Drug
M5049
M5049: highest development phase Phase 1, developed by Merck. 3 trial records tracked on RxWires.
- Highest phase
- Phase 1
- Developer
- Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| M5049 NCT03676322 | Phase 1 | Healthy |
| M5049 NCT04647708 | Phase 1 | Systemic Lupus Erythematosus |
| M5049 NCT04880213 | Phase 1 | Healthy |
Latest
No recent events.
Follow M5049 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.